This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Non-Hodgkin lymphoma
  • /
  • Guidelines on the diagnosis and management of Wald...

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia

Read time: 1 mins
Last updated:11th Jan 2022
Diagnosis and management of Waldenström macroglobulinaemia - A British Society for Haematology guideline

The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with Waldenström macroglobulinaemia. In individual patients, circumstances may dictate an alternative approach.

Waldenström macroglobulinaemia (WM) is a distinct B-cell lymphoproliferative disorder characterised by an immunoglobulin IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic lymphoma (LPL).1, 2 Clinical features may be related to overall disease burden, such as anaemia, constitutional symptoms, or may be directly attributable to the IgM paraprotein. The term IgM-related disorders denotes the presence of clinical features attributable to the IgM paraprotein in the absence of bone marrow lymphoplasmacytic infiltration.1

Read full Guideline